Telo Genomics Corp. (TELO.V)
CAD 0.12
(0.0%)
CAD 0.12
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.66 Million CAD | 4.26% |
| 2022 | -2.78 Million CAD | -35.75% |
| 2021 | -2.04 Million CAD | -103.02% |
| 2020 | -1 Million CAD | 12.08% |
| 2019 | -1.15 Million CAD | -18.53% |
| 2018 | -970.61 Thousand CAD | 77.84% |
| 2017 | -4.48 Million CAD | 48.98% |
| 2016 | -9.79 Million CAD | -11582.43% |
| 2015 | -1.65 Million CAD | 34.29% |
| 2014 | -315.18 Thousand CAD | -571.6% |
| 2013 | -16.65 Thousand CAD | 77.38% |
| 2012 | -73.61 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q3 | -605.17 Thousand CAD | 26.51% |
| 2023 Q1 | -662.23 Thousand CAD | 21.6% |
| 2023 Q4 | -589.31 Thousand CAD | 2.62% |
| 2023 Q2 | -823.43 Thousand CAD | -24.34% |
| 2022 Q3 | -701.88 Thousand CAD | -11.16% |
| 2022 Q4 | -844.69 Thousand CAD | -20.35% |
| 2022 FY | - CAD | -35.75% |
| 2022 Q1 | -609.65 Thousand CAD | 5.09% |
| 2022 Q2 | -631.43 Thousand CAD | -3.57% |
| 2021 Q1 | -462.95 Thousand CAD | -69.8% |
| 2021 FY | - CAD | -103.02% |
| 2021 Q4 | -642.35 Thousand CAD | -28.21% |
| 2021 Q3 | -501 Thousand CAD | -12.04% |
| 2021 Q2 | -447.18 Thousand CAD | 3.41% |
| 2020 Q4 | -272.65 Thousand CAD | 7.24% |
| 2020 FY | - CAD | 12.08% |
| 2020 Q3 | -293.93 Thousand CAD | -13.8% |
| 2020 Q2 | -258.29 Thousand CAD | -41.49% |
| 2020 Q1 | -182.55 Thousand CAD | 37.26% |
| 2019 Q1 | -122.46 Thousand CAD | 16.26% |
| 2019 FY | - CAD | -18.53% |
| 2019 Q4 | -290.98 Thousand CAD | 4.67% |
| 2019 Q3 | -305.24 Thousand CAD | 43.98% |
| 2019 Q2 | -544.86 Thousand CAD | -344.92% |
| 2018 Q2 | -158.27 Thousand CAD | 71.76% |
| 2018 Q1 | -560.41 Thousand CAD | 42.09% |
| 2018 FY | - CAD | 77.84% |
| 2018 Q4 | -146.24 Thousand CAD | -38.4% |
| 2018 Q3 | -105.66 Thousand CAD | 33.24% |
| 2017 Q4 | -967.68 Thousand CAD | -22.36% |
| 2017 Q1 | -1.03 Million CAD | 51.17% |
| 2017 FY | - CAD | 48.98% |
| 2017 Q2 | -1.49 Million CAD | -43.69% |
| 2017 Q3 | -790.86 Thousand CAD | 46.98% |
| 2016 Q4 | -2.12 Million CAD | 0.46% |
| 2016 Q3 | -2.13 Million CAD | -34.81% |
| 2016 Q2 | -1.58 Million CAD | 52.61% |
| 2016 Q1 | -3.34 Million CAD | -17406.36% |
| 2016 FY | - CAD | -11582.43% |
| 2015 Q2 | -60.91 Thousand CAD | -2845.25% |
| 2015 Q1 | 2219.00 CAD | 126.58% |
| 2015 FY | - CAD | 34.29% |
| 2015 Q4 | -19.09 Thousand CAD | 58.35% |
| 2015 Q3 | -45.84 Thousand CAD | 24.74% |
| 2014 Q3 | -6445.00 CAD | 63.81% |
| 2014 Q2 | -17.8 Thousand CAD | -45.55% |
| 2014 FY | - CAD | -571.6% |
| 2014 Q1 | -12.23 Thousand CAD | 53.36% |
| 2014 Q4 | -8348.00 CAD | -29.53% |
| 2013 Q3 | -55.57 Thousand CAD | -744.54% |
| 2013 Q1 | -4498.00 CAD | 64.2% |
| 2013 FY | - CAD | 77.38% |
| 2013 Q4 | -26.23 Thousand CAD | 52.79% |
| 2013 Q2 | -6580.00 CAD | -46.29% |
| 2012 Q4 | -12.56 Thousand CAD | -66.59% |
| 2012 Q3 | -7542.00 CAD | -170.18% |
| 2012 Q2 | 10.74 Thousand CAD | 243.75% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q1 | -7476.00 CAD | 41.98% |
| 2011 Q3 | -88.67 Thousand CAD | 0.0% |
| 2011 Q4 | -12.88 Thousand CAD | 85.47% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Avricore Health Inc. | -275.13 Thousand CAD | -870.008% |